Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3
- 1 September 2003
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (18) , 3049-3053
- https://doi.org/10.1016/s0960-894x(03)00644-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Regulation of Angiogenesis by Glycogen Synthase Kinase-3βPublished by Elsevier ,2002
- Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammationMedicinal Research Reviews, 2002
- Protein kinase C inhibitors as novel anticancer drugsExpert Opinion on Investigational Drugs, 2001
- The multifaceted roles of glycogen synthase kinase 3β in cellular signalingPublished by Elsevier ,2001
- ATP site-directed competitive and irreversible inhibitors of protein kinasesMedicinal Research Reviews, 2000
- LY-333531 Mesylate HydrateDrugs of the Future, 2000
- Macrocyclic Bisindolylmaleimides: Synthesis by Inter- and Intramolecular AlkylationThe Journal of Organic Chemistry, 1998
- Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β InhibitorScience, 1996
- (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase CβJournal of Medicinal Chemistry, 1996